Egetis Therapeutics AB (publ) reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported sales was SEK 32.6 million compared to SEK 5.7 million a year ago. Revenue was SEK 32.6 million compared to SEK 5.7 million a year ago.

Net loss was SEK 86.3 million compared to SEK 77.8 million a year ago. Basic loss per share from continuing operations was SEK 0.3 compared to SEK 0.4 a year ago. Diluted loss per share from continuing operations was SEK 0.3 compared to SEK 0.4 a year ago.